Skip to main content

Kenvue’s stock hits fresh post-IPO lows as Tylenol parent company receives tepid reviews from analysts

Kenvue's stock hit new lows as Wall Street analysts start coverage of the Johnson & Johnson spinoff with halfhearted ratings.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.